ApolloBio has signed an amended agreement to obtain exclusive development and commercialisation rights for Inovio Pharmaceuticals’ VGX-3100 in Greater China, comprising China, Hong Kong, Macao and Taiwan.

The agreement involves an option for potential inclusion of the Republic of Korea in the next three years.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

VGX-3100 is a DNA immunotherapy product formulated for the treatment of pre-cancers caused by human papillomavirus (HPV).

It is currently being developed as a non-surgical therapy for high-grade cervical dysplasia and associated underlying persistent HPV infection.

Under the latest agreement, Inovio will receive an upfront payment of $23m from ApolloBio, along with potential milestone payments of up to $20m in the future.

“In addition, this collaborative agreement with ApolloBio could potentially accelerate our overall global VGX-3100 efforts by accessing clinical study patients in China.”

The deal, which replaces the original agreement signed in November last year, covers development of the product for treatment and/or prevention of pre-cancerous HPV infections and HPV-driven dysplasias such as cervical, vulvar and anal pre-cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The amendment, however, excludes HPV-driven cancers and combinations of VGX-3100 with other immunostimulants.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “We are pleased to move forward with an agreement that preserves the best interest for our shareholders by obtaining a greater upfront non-dilutive cash licence fee of $23m and removing the equity provisions.

“In addition, this collaborative agreement with ApolloBio could potentially accelerate our overall global VGX-3100 efforts by accessing clinical study patients in China.”

The firm expects to close the agreement in the first quarter of this year.